Metin Çelik, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Metin Çelik, PhD


Metin Çelik, PhD
President, Pharmaceutical
Technologies
International (PTI)

Metin Çelik is the founder and president of Pharmaceutical Technologies International, Inc., and is also a pharmaceutical processing research professor in the Department of Industrial Engineering at Rutgers University. Prior to that, he was a faculty member at Rutgers’ College of Pharmacy. Çelik received his BSc (Hons.) degree in pharmacy from Hacettepe University-Turkey and was awarded a PhD degree in Pharmaceutical Technology from Leicester Polytechnic-UK. Çelik worked at Sandoz-Switzerland and Sandoz-Turkey before he joined Smith Kline & French Laboratories to establish the first state-of-the-art compaction simulator system in the western hemisphere. He developed the second unit at Rutgers as the first such a unit in academia in the US and established an internationally recognized research center.

Çelik has organized more than 40 national and international symposia and short courses, published more than 30 research articles and book chapters, and made more than 150 presentations at industry and academic meetings. Çelik acted a consultant to FDA and roughly 45 pharmaceutical, nutraceutical, excipient, equipment companies, and law firms worldwide. He currently serves as a member of the editorial board or a reviewer for a numerous pharmaceutical journals. He is the past chair of the American Association of Pharmaceutical Scientists (AAPS) Process Development Focus Group and the founder and the past chair of the AAPS Excipients Focus Group.

Çelik's recent areas of interests include: process analytical technology; development of pharmaceutical expert systems, excipient databases, and management tools in the area of drug delivery technologies; use of compaction simulators in the preformulation and formulation of solid dosage forms; theory and practice of pharmaceutical compaction; excipient functionality testing; and pharmaceutical processing (including milling, mixing, granulation, tableting, and coating).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search

Click here